1
|
Tautou M, Descamps F, Larchanché PE, Buée L, El Bakali J, Melnyk P, Sergeant N. A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology. Int J Mol Sci 2023; 24:ijms24065285. [PMID: 36982363 PMCID: PMC10048993 DOI: 10.3390/ijms24065285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 02/03/2023] [Accepted: 02/15/2023] [Indexed: 03/12/2023] Open
Abstract
The progress in Alzheimer’s disease (AD) treatment suggests a combined therapeutic approach targeting the two lesional processes of AD, which include amyloid plaques made of toxic Aβ species and neurofibrillary tangles formed of aggregates of abnormally modified Tau proteins. A pharmacophoric design, novel drug synthesis, and structure-activity relationship enabled the selection of a polyamino biaryl PEL24-199 compound. The pharmacologic activity consists of a non-competitive β-secretase (BACE1) modulatory activity in cells. Curative treatment of the Thy-Tau22 model of Tau pathology restores short-term spatial memory, decreases neurofibrillary degeneration, and alleviates astrogliosis and neuroinflammatory reactions. Modulatory effects of PEL24-199 towards APP catalytic byproducts are described in vitro, but whether PEL24-199 can alleviate the Aβ plaque load and associated inflammatory counterparts in vivo remains to be elucidated. We investigated short- and long-term spatial memory, Aβ plaque load, and inflammatory processes in APPSwe/PSEN1ΔE9 PEL24-199 treated transgenic model of amyloid pathology to achieve this objective. PEL24-199 curative treatment induced the recovery of spatial memory and decreased the amyloid plaque load in association with decreased astrogliosis and neuroinflammation. The present results underline the synthesis and selection of a promising polyaminobiaryl-based drug that modulates both Tau and, in this case, APP pathology in vivo via a neuroinflammatory-dependent process.
Collapse
Affiliation(s)
- Marie Tautou
- Univ. Lille, Inserm, CHU Lille, UMRS1172—LilNCog—Lille Neuroscience & Cognition, 59000 Lille, France
| | - Florian Descamps
- Univ. Lille, Inserm, CHU Lille, UMRS1172—LilNCog—Lille Neuroscience & Cognition, 59000 Lille, France
| | - Paul-Emmanuel Larchanché
- Univ. Lille, Inserm, CHU Lille, UMRS1172—LilNCog—Lille Neuroscience & Cognition, 59000 Lille, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, UMRS1172—LilNCog—Lille Neuroscience & Cognition, 59000 Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, 59045 Lille, France
| | - Jamal El Bakali
- Univ. Lille, Inserm, CHU Lille, UMRS1172—LilNCog—Lille Neuroscience & Cognition, 59000 Lille, France
| | - Patricia Melnyk
- Univ. Lille, Inserm, CHU Lille, UMRS1172—LilNCog—Lille Neuroscience & Cognition, 59000 Lille, France
- Correspondence: (P.M.); (N.S.); Tel.: +33-663101728 (N.S.)
| | - Nicolas Sergeant
- Univ. Lille, Inserm, CHU Lille, UMRS1172—LilNCog—Lille Neuroscience & Cognition, 59000 Lille, France
- Alzheimer & Tauopathies, LabEx DISTALZ, 59045 Lille, France
- Correspondence: (P.M.); (N.S.); Tel.: +33-663101728 (N.S.)
| |
Collapse
|
2
|
Tautou M, Eddarkaoui S, Descamps F, Larchanché PE, El Bakali J, Goveas LM, Dumoulin M, Lamarre C, Blum D, Buée L, Melnyk P, Sergeant N. A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. Front Pharmacol 2021; 12:679335. [PMID: 34267657 PMCID: PMC8276176 DOI: 10.3389/fphar.2021.679335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Accepted: 05/18/2021] [Indexed: 01/24/2023] Open
Abstract
Identifying which among several in cellulo pharmacological activities is necessary for the proper in vivo activity is essential for further drug development against Alzheimer’s disease pathophysiological processes. An in-depth structure–activity relationship–based study has been carried out, and two molecules, named MAGS02-14 and PEL24-199, that share a ß-secretase modulatory effect associated or not to a lysosomotropic activity in cellulo have been identified. In terms of chemical formulas, MAGS02-14 and PEL24-199 only differ from each other by a single nitrogen atom. The study aimed to elucidate the in vivo pharmacological effects of lysosomotropic and/or the ß-secretase modulatory activity in a tau pathology mouse model. To address this question, the THY-Tau22 transgenic model of tauopathy was treated with both compounds for 6 weeks in a curative paradigm. Short-term memory, tau burden, and inflammatory processes were analyzed using orthogonal methods, and PEL24-199, but not MAGS02-14, was shown to restore the short-term memory and reduce the neurofibrillary degenerating process. These effects were associated with a reduced phosphorylation of tau, an increased phosphatase expression, and decreased astrogliosis. Our results, therefore, suggest that the lysosomotropic activity may be nonessential for the effect on tau pathology.
Collapse
Affiliation(s)
- Marie Tautou
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Sabiha Eddarkaoui
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| | - Florian Descamps
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Paul-Emmanuel Larchanché
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Jamal El Bakali
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Liesel Mary Goveas
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Mélanie Dumoulin
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Chloé Lamarre
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - David Blum
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| | - Luc Buée
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| | - Patricia Melnyk
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France
| | - Nicolas Sergeant
- Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience and Cognition, University of Lille, Lille, France.,Alzheimer and Tauopathies, LabEx DISTALZ, Lille, France
| |
Collapse
|
3
|
Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P. New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. Neurobiol Dis 2019; 129:217-233. [PMID: 30928644 DOI: 10.1016/j.nbd.2019.03.028] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Revised: 03/01/2019] [Accepted: 03/26/2019] [Indexed: 12/01/2022] Open
Abstract
Alzheimer's Disease is a devastating dementing disease involving amyloid deposits, neurofibrillary tangles, progressive and irreversible cognitive impairment. Today, only symptomatic drugs are available and therapeutic treatments, possibly acting at a multiscale level, are thus urgently needed. To that purpose, we designed multi-effects compounds by synthesizing drug candidates derived by substituting a novel N,N'-disubstituted piperazine anti-amyloid scaffold and adding acetylcholinesterase inhibition property. Two compounds were synthesized and evaluated. The most promising hybrid molecule reduces both the amyloid pathology and the Tau pathology as well as the memory impairments in a preclinical model of Alzheimer's disease. In vitro also, the compound reduces the phosphorylation of Tau and inhibits the release of Aβ peptides while preserving the processing of other metabolites of the amyloid precursor protein. We synthetized and tested the first drug capable of ameliorating both the amyloid and Tau pathology in animal models of AD as well as preventing the major brain lesions and associated memory impairments. This work paves the way for future compound medicines against both Alzheimer's-related brain lesions development and the associated cognitive impairments.
Collapse
Affiliation(s)
- Nicolas Sergeant
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France.
| | - Valérie Vingtdeux
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Sabiha Eddarkaoui
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Marion Gay
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Caroline Evrard
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Nicolas Le Fur
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Cyril Laurent
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Raphaelle Caillierez
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Hélène Obriot
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Paul-Emmanuel Larchanché
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Amaury Farce
- Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France
| | - Mathilde Coevoet
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Pascal Carato
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Mostafa Kouach
- Univ. Lille, CUMA - Centre Universitaire de Mesures et d'Analyses, F-59000 Lille, France
| | - Amandine Descat
- Univ. Lille, CUMA - Centre Universitaire de Mesures et d'Analyses, F-59000 Lille, France
| | - Patrick Dallemagne
- UNICAEN, UFR des Sciences Pharmaceutiques, EA 4258 CERMN, F-14032 Caen, France
| | - Valérie Buée-Scherrer
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - David Blum
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Malika Hamdane
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France
| | - Patricia Melnyk
- Univ. Lille, Inserm, CHU Lille, UMR-S1172 - JPArc - Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, F-59000 Lille, France.
| |
Collapse
|
4
|
Gay M, Carato P, Coevoet M, Renault N, Larchanché PE, Barczyk A, Yous S, Buée L, Sergeant N, Melnyk P. New phenylaniline derivatives as modulators of amyloid protein precursor metabolism. Bioorg Med Chem 2018; 26:2151-2164. [PMID: 29559198 DOI: 10.1016/j.bmc.2018.03.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 03/08/2018] [Accepted: 03/10/2018] [Indexed: 11/25/2022]
Abstract
The chloroquinoline scaffold is characteristic of anti-malarial drugs such as chloroquine (CQ) or amodiaquine (AQ). These drugs are also described for their potential effectiveness against prion disease, HCV, EBV, Ebola virus, cancer, Parkinson or Alzheimer diseases. Amyloid precursor protein (APP) metabolism is deregulated in Alzheimer's disease. Indeed, CQ modifies amyloid precursor protein (APP) metabolism by precluding the release of amyloid-beta peptides (Aβ), which accumulate in the brain of Alzheimer patients to form the so-called amyloid plaques. We showed that AQ and analogs have similar effects although having a higher cytotoxicity. Herein, two new series of compounds were synthesized by replacing 7-chloroquinolin-4-amine moiety of AQ by 2-aminomethylaniline and 2-aminomethylphenyle moieties. Their structure activity relationship was based on their ability to modulate APP metabolism, Aβ release, and their cytotoxicity similarly to CQ. Two compounds 15a, 16a showed interesting and potent effect on the redirection of APP metabolism toward a decrease of Aβ peptide release (in the same range compared to AQ), and a 3-10-fold increased stability of APP carboxy terminal fragments (CTFα and AICD) without obvious cellular toxicity at 100 µM.
Collapse
Affiliation(s)
- Marion Gay
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Pascal Carato
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Mathilde Coevoet
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Nicolas Renault
- Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France
| | - Paul-Emmanuel Larchanché
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Amélie Barczyk
- Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France
| | - Saïd Yous
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Luc Buée
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Nicolas Sergeant
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
| | - Patricia Melnyk
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| |
Collapse
|
5
|
Donnier-Maréchal M, Carato P, Larchanché PE, Ravez S, Boulahjar R, Barczyk A, Oxombre B, Vermersch P, Melnyk P. Synthesis and pharmacological evaluation of benzamide derivatives as potent and selective sigma-1 protein ligands. Eur J Med Chem 2017; 138:964-978. [PMID: 28756263 DOI: 10.1016/j.ejmech.2017.07.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Revised: 05/22/2017] [Accepted: 07/10/2017] [Indexed: 02/08/2023]
Abstract
A series of novel benzamide-derived compounds was designed, synthesized and pharmacologically evaluated. Among all 37 synthesized compounds, two series were developed with the modulation of the nature, the position of atoms or groups on the benzamide scaffold, but also the nature of the amine group separated from the benzamide with 2, 3 or 4 methylene groups. In vitro competition binding assays against sigma proteins (sigma-1 S1R and sigma-2 S2R) revealed that most of them conferred S2R/S1R selectivity toward without cytotoxic effects on SY5Y cells, especially with the first series with compounds 7a-z. Some selected compounds were also evaluated for their agonist and antagonist activities on a panel of 40 receptors. Results showed the importance of the nature and the position with halogeno atom on the benzamide scaffold, the length chain but also the contribution of the hydrophobic part on the amine group. Among them, compounds 7i, w, y with Cl, CN or NO2 groups at the 4-position of the benzamide scaffold showed excellent affinity for S1R (Ki = 1.2-3.6 nM), selectivity for S2R (Ki up to 1400 nM) and high selectivity index (IC50(SY5Y)/Ki(S1R) ratio from 28 000 to 83 000). Futhermore, these compounds presented an excellent safety profile over 40 other receptors. These derivatives will be selected for further biological investigations.
Collapse
Affiliation(s)
- Marion Donnier-Maréchal
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| | - Pascal Carato
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| | - Paul-Emmanuel Larchanché
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| | - Séverine Ravez
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| | - Rajaa Boulahjar
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| | - Amélie Barczyk
- Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France.
| | - Bénédicte Oxombre
- Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France.
| | - Patrick Vermersch
- Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France.
| | - Patricia Melnyk
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| |
Collapse
|
6
|
Danel C, Melnyk P, Azaroual N, Larchanché PE, Goossens JF, Vaccher C. Evaluation of three neutral capillary coatings for the determination of analyte-cyclodextrin binding constants by affinity capillary electrophoresis. Application to N,N'-disubstituted piperazine derivatives. J Chromatogr A 2016; 1455:163-171. [PMID: 27286645 DOI: 10.1016/j.chroma.2016.05.090] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 05/23/2016] [Accepted: 05/26/2016] [Indexed: 01/08/2023]
Abstract
The performances of three neutral static coatings (hydroxypropyl cellulose, polyethylene oxide and poly(N,N-dimethylacrylamide) have been evaluated in order to determine the binding constants of the complexes formed between four polycationic compounds (piperazine derivatives) and four cyclodextrins of pharmaceutical interest (β-CD, HP-β-CD, Me-β-CD and sulfobutyl ether-β-CD) by affinity capillary electrophoresis. The physically-adsorbed poly(N,N-dimethylacrylamide) coating proves to be the more efficient to mask the silanol groups of the capillary wall since the lowest electroosmotic flow was measured for this coating. Moreover, it drastically reduces the adsorption of the compounds since it allows a correct repeatability of their migration time, higher efficiencies of the peaks and no baseline shift. Then, it was verified for four complexes that this coating allows a correct determination of the binding constants avoiding the CD adsorption which is responsible of an undervaluation of binding constants. The highest binding constants are obtained using the anionic sulfobutyl ether-β-CD (SBE-β-CD). The structure of the complex formed between the tacrine derivative and the SBE-β-CD was further investigated through 2D ROESY NMR experiments and structure-binding constant relationships. Results suggest that the inclusion in the SBE-β-CD cavity occurs through the aliphatic ring portion of the tacrine moiety.
Collapse
Affiliation(s)
- Cécile Danel
- Univ. Lille, CHU Lille, EA 7365 GRITA Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.
| | - Patricia Melnyk
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 JPArc Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| | - Nathalie Azaroual
- Univ. Lille, CHU Lille, EA 7365 GRITA Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.
| | - Paul-Emmanuel Larchanché
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172 JPArc Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France.
| | - Jean-François Goossens
- Univ. Lille, CHU Lille, EA 7365 GRITA Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.
| | - Claude Vaccher
- Univ. Lille, CHU Lille, EA 7365 GRITA Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France.
| |
Collapse
|
7
|
Melnyk P, Vingtdeux V, Burlet S, Eddarkaoui S, Grosjean ME, Larchanché PE, Hochart G, Sergheraert C, Estrella C, Barrier M, Poix V, Plancq P, Lannoo C, Hamdane M, Delacourte A, Verwaerde P, Buée L, Sergeant N. Chloroquine and chloroquinoline derivatives as models for the design of modulators of amyloid Peptide precursor metabolism. ACS Chem Neurosci 2015; 6:559-69. [PMID: 25611616 DOI: 10.1021/cn5003013] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The amyloid precursor protein (APP) plays a central role in Alzheimer's disease (AD). Preventing deregulated APP processing by inhibiting amyloidogenic processing of carboxy-terminal fragments (APP-CTFs), and reducing the toxic effect of amyloid beta (Aβ) peptides remain an effective therapeutic strategy. We report the design of piperazine-containing compounds derived from chloroquine structure and evaluation of their effects on APP metabolism and ability to modulate the processing of APP-CTF and the production of Aβ peptide. Compounds which retained alkaline properties and high affinity for acidic cell compartments were the most effective. The present study demonstrates that (1) the amino side chain of chloroquine can be efficiently substituted by a bis(alkylamino)piperazine chain, (2) the quinoline nucleus can be replaced by a benzyl or a benzimidazole moiety, and (3) pharmacomodulation of the chemical structure allows the redirection of APP metabolism toward a decrease of Aβ peptide release, and increased stability of APP-CTFs and amyloid intracellular fragment. Moreover, the benzimidazole compound 29 increases APP-CTFs in vivo and shows promising activity by the oral route. Together, this family of compounds retains a lysosomotropic activity which inhibits lysosome-related Aβ production, and is likely to be beneficial for therapeutic applications in AD.
Collapse
Affiliation(s)
- Patricia Melnyk
- Université de Lille, F-59000 Lille, France
- UDSL, EA 4481,
UFR Pharmacie, F-59000 Lille, France
- CNRS UMR8161, F-59000 Lille, France
| | - Valérie Vingtdeux
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | | | - Sabiha Eddarkaoui
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | - Marie-Eve Grosjean
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | | | - Guillaume Hochart
- Université de Lille, F-59000 Lille, France
- UDSL, EA 4481,
UFR Pharmacie, F-59000 Lille, France
- CNRS UMR8161, F-59000 Lille, France
| | | | | | | | | | | | | | - Malika Hamdane
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | - André Delacourte
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | | | - Luc Buée
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| | - Nicolas Sergeant
- Université de Lille, F-59000 Lille, France
- Inserm UMR-S1172, Alzheimer & Tauopathies, Jean-Pierre Aubert Research Center, F-59000 Lille, France
| |
Collapse
|
8
|
Donnier-Maréchal M, Larchanché PE, Le Broc D, Furman C, Carato P, Melnyk P. Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands. Eur J Med Chem 2015; 89:198-206. [PMID: 25462240 DOI: 10.1016/j.ejmech.2014.10.053] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2014] [Revised: 10/16/2014] [Accepted: 10/17/2014] [Indexed: 10/24/2022]
Abstract
Sigma 1 receptors are associated with neurodegenerative and psychiatric disorders. These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents. The involvement of these receptors has also been observed in neuropathic pain and cancer. Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clinical trials. Thus the development of sigma 1 ligands is of interest to a new generation of drugs. Previous work in our lab underlined the potency of benzannulated bicyclic compounds as interesting ligands. Herein the work was extended to a series of novel tricyclic compounds. Carboline- and phenothiazine-derivated compounds were designed and synthesized. In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (Ki = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells.
Collapse
Affiliation(s)
- Marion Donnier-Maréchal
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| | - Paul-Emmanuel Larchanché
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| | - Delphine Le Broc
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4483, UFR Pharmacie, F-59000 Lille, France.
| | - Christophe Furman
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4483, UFR Pharmacie, F-59000 Lille, France.
| | - Pascal Carato
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| | - Patricia Melnyk
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| |
Collapse
|
9
|
Le Fur N, Hochart G, Larchanché PE, Melnyk P. Buchwald reaction as the key step for the synthesis of metabolically more stable analogs of amodiaquine. Eur J Med Chem 2011; 46:3052-7. [DOI: 10.1016/j.ejmech.2011.04.047] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2011] [Revised: 04/14/2011] [Accepted: 04/15/2011] [Indexed: 11/30/2022]
|
10
|
Fur NL, Larchanché PE, Melnyk P. Optimized and convergent synthesis of potent anti-malarial aminoquinoline compounds: easy access to analogs. HETEROCYCL COMMUN 2010. [DOI: 10.1515/hc.2010.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|